Cargando…

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects

INTRODUCTION: Latanoprostene bunod is a novel nitric oxide (NO)-donating prostaglandin F2α receptor agonist in clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. We evaluated the effect of latanoprostene bunod 0.024% inst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Araie, Makoto, Sforzolini, Baldo Scassellati, Vittitow, Jason, Weinreb, Robert N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662725/ https://www.ncbi.nlm.nih.gov/pubmed/26563323 http://dx.doi.org/10.1007/s12325-015-0260-y

Ejemplares similares

Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
por: Kawase, Kazuhide, et al.
Publicado: (2016)

Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis, Victoria M, et al.
Publicado: (2018)

Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension
por: Fingeret, Murray, et al.
Publicado: (2019)

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis
por: Lo, Tzu-Chen, et al.
Publicado: (2022)

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
por: Weinreb, Robert N, et al.
Publicado: (2015)

Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma
por: Okeke, Constance O., et al.
Publicado: (2020)

Critical evaluation of latanoprostene bunod in the treatment of glaucoma
por: Garcia, Giancarlo A, et al.
Publicado: (2016)

The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
por: Cavet, Megan E., et al.
Publicado: (2018)

Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma
por: Zhou, Benjamin, et al.
Publicado: (2022)

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
por: Wang, Yulong, et al.
Publicado: (2020)

Reply to Hall J: “Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population”: Virender S. Sangwan, P. Andrew Pearson, Hemanth Paul, Timothy L. Comstock
por: Scassellati Sforzolini, Baldo
Publicado: (2015)

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
por: Harasymowycz, Paul, et al.
Publicado: (2022)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra, Ranjan P, et al.
Publicado: (2019)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier, Edward J, et al.
Publicado: (2018)

Magnetostrictive Properties of Mn(0.70)Zn(0.24)Fe(2.06)O(4) Ferrite
por: Bieńkowski, Adam, et al.
Publicado: (2018)

EHMTI-0024. The typical duration of migraine aura: a prospective diary-based study
por: Viana, M, et al.
Publicado: (2014)

Y(0.76)Ho(0.24)FeGe(2)O(7): a new member of thortveitite-like layered compounds
por: Rosales, Ivonne, et al.
Publicado: (2009)

Influence of Nb on the Microstructure and Fracture Toughness of (Zr(0.76)Fe(0.24))(100−x)Nb(x) Nano-Eutectic Composites
por: Maity, Tapabrata, et al.
Publicado: (2018)

Poly[[bis(μ-4,4′-bipyridine-κ(2) N:N′)copper(I)] perchlorate 0.24-hydrate]
por: Zhang, Chun-Yan, et al.
Publicado: (2012)

A Schottky-Type Metal-Semiconductor-Metal Al(0.24)Ga(0.76)N UV Sensor Prepared by Using Selective Annealing
por: Park, Byeong-Jun, et al.
Publicado: (2021)

Monitoring nitrite, N-nitrosodiethanolamine, and mutagenicity in cutting fluids used in the metal industry.
por: Monarca, S, et al.
Publicado: (1993)

Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
por: Araie, Makoto, et al.
Publicado: (2021)

Single cavity design for the quasi-Alvarez Linac between 0.24MeV/u and 4.2 MeV/u
por: Warner, D J, et al.
Publicado: (1991)

Synthesis of WS(1.76)Te(0.24) alloy through chemical vapor transport and its high-performance saturable absorption
por: Du, Zhengting, et al.
Publicado: (2019)

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
por: Dubiner, Harvey B, et al.
Publicado: (2012)

Diurnal and 24-h Intraocular Pressures in Glaucoma: Monitoring Strategies and Impact on Prognosis and Treatment
por: Konstas, Anastasios G., et al.
Publicado: (2018)

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
por: Fong, Raymond, et al.
Publicado: (2019)

Professional Identity of 0.24 Million Medical Students in China Before and During the COVID-19 Pandemic: Three Waves of National Cross-Sectional Studies
por: Yu, Chen, et al.
Publicado: (2022)

Efficacy of a Contact Lens Sensor for Monitoring 24-H Intraocular Pressure Related Patterns
por: Mansouri, Kaweh, et al.
Publicado: (2015)

Biological monitoring of workers exposed to N-nitrosodiethanolamine in the metal industry.
por: Monarca, S, et al.
Publicado: (1996)

Efficient One-Step Synthesis of a Pt-Free Zn(0.76)Co(0.24)S Counter Electrode for Dye-Sensitized Solar Cells and Its Versatile Application in Photoelectrochromic Devices
por: Tashenov, Yerbolat, et al.
Publicado: (2023)

Estimation of 24-Hour Intraocular Pressure Peak Timing and Variation Using a Contact Lens Sensor
por: Liu, John H. K., et al.
Publicado: (2015)

Letrozole in the neoadjuvant setting: the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Letrozole in the neoadjuvant setting the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma
por: Francis, Jasmine H., et al.
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

CMS ARDA Meeting, ARDA-Note-2004-024
por: CERN. Geneva
Publicado: (2004)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jkfqpkuvnhbusst26ia8q0bdhe